Berenberg Bank Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)
In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Black Diamond Therapeutics (BDTX), with a price target of $58.00. The company’s shares closed last Friday at $25.59.
According to TipRanks.com, Shu is a 3-star analyst with an average return of 8.1% and a 34.2% success rate. Shu covers the Healthcare sector, focusing on stocks such as Sensei Biotherapeutics, Repare Therapeutics, and Kymera Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Black Diamond Therapeutics with a $50.60 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.25 and a one-year low of $21.04. Currently, Black Diamond Therapeutics has an average volume of 326.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.